First-Line Treatment of Irritant Contact Dermatitis
Irritant contact dermatitis (ICD-10 L24 / ICD-11 EK02) presents with localised inflammatory skin changes and is managed with a first-line topical approach. The choice of agent is guided primarily by the site of involvement and the characteristics of the affected skin.
Treatment approach
The first-line approach centres on topical corticosteroid therapy. Potency is selected according to the anatomical location of lesions — areas with thinner or more sensitive skin call for a different, lower-potency choice compared with typical body sites, in order to minimise adverse effects.
References
- Localized acute allergic contact dermatitis lesions are successfully treated with mid- or high-potency topical steroids, such as triamcinolone 0.1% (Kenalog, Aristocort) or clobetasol 0.05% (Temovate).
- On areas with thinner skin (e.g., flexural surfaces, eyelids, face, anogenital region), lower-potency steroids, such as desonide ointment (Desowen), can be helpful and minimize the risk of skin atrophy.
- There are insufficient data to support the use of topical steroids for irritant contact dermatitis.
- However, because it is difficult to clinically distinguish between allergic and irritant contact dermatitis, these agents are often used successfully for the irritant form.